Novel quinazolinone compound as well as preparation method and application thereof

A quinazolinone and compound technology, applied in the field of novel quinazolinone compounds and their preparation, can solve the problems of high onset concentration, unclear mode of action, and small quantity, and achieve DNA damage induction and normal cell toxicity Small, strong selective effects

Active Publication Date: 2019-12-20
SUN YAT SEN UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The currently reported BLM inhibitors, on the one hand, are small in number; on the other hand, there are prob...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel quinazolinone compound as well as preparation method and application thereof
  • Novel quinazolinone compound as well as preparation method and application thereof
  • Novel quinazolinone compound as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Preparation of compound 1f

[0043] The preparation process of compound 1f is as follows:

[0044] S1, synthesis of intermediate d1

[0045]

[0046] 4.2 g (24.3 mmol) of 2-amino-4,5-difluorobenzoic acid was added to a 100 mL reaction flask containing 12 mL of acetic anhydride, and reacted at 120° C. for 1.5 hours. After cooling, a large amount of white solid precipitated. The reaction solution was rotary evaporated under reduced pressure to remove most of the acetic anhydride, and a large amount of white solid appeared, which was filtered with suction and washed with ethanol to obtain a white solid d1, which was directly used for the next reaction.

[0047] 1 H NMR (400MHz, DMSO) δ 8.13 (dd, J = 9.9, 8.5 Hz, 1H), 7.74 (dd, J = 11.1, 7.2 Hz, 1H), 2.40 (s, 3H).

[0048] S2, the synthesis of intermediate d2

[0049]

[0050] Take 1g of d1 (5.07mmol) and 9mL of ammonia in a 100mL reaction flask, condense and reflux at 70°C (a balloon is placed on the condenser to prevent ...

Embodiment 2

[0079] Example 2 EMSA verification helicase activity experiment

[0080] The compound prepared in Example 1 was used as the test object to test its ability to inhibit the unwinding of BLM.

[0081] 1. Anneal the double-stranded Biotin forked-DNA with a final concentration of 10nM at 95°C for 5min and slowly lower the temperature to room temperature to form a stable double helix structure;

[0082] 2. Mix the purified BLM protein and the compounds of different concentrations in the helicase working solution, and incubate them at 37°C for 1 h. The final concentration of the protein is 30 nM, and then mix the protein compound solution with the DNA solution, and mix. After homogenization, continue to incubate at 37℃ for 1h;

[0083] 3. After the incubation, add DNA Loading buffer to the sample to end the enzymatic reaction. After mixing well, load the sample to 8% Native-PAGE, buffer 0.5×TB, 80V ice bath for about 3h, to bromine The phenol blue band is close to the edge of the electropho...

Embodiment 3

[0087] Example 3 MTT experiment

[0088] 1. Inoculate HCT116 cells in logarithmic growth phase on a 96-well cell culture plate with 5000 cells / well, and place them in an incubator containing 5% CO2 for 24 hours;

[0089] 2. After the cells are completely attached to the wall, discard the old medium, add medium containing different concentrations of compounds, and culture for different times according to the requirements of different experiments;

[0090] 3. When testing, add 20μL of MTT solution with a concentration of 2.5mg / mL to each well of cells and continue to incubate at 37°C for 4h;

[0091] 4. After the MTT incubation, discard the old culture medium and add 100μL of DMSO to each well. At this time, the solution in the well is purple. After shaking evenly, use a multifunctional microplate reader to detect the absorption value of each well at 570nm wavelength, and obtain the half inhibitory concentration IC of the compound on cell proliferation according to the relationship betw...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel quinazolinone compound as well as a preparation method and application thereof. The structure of the compound is as shown in a formula I, wherein R is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-6 amino substituted alkyl, alkyl or alkyl amino; R2 is hydrogen, C1-4 alkyl or C1-4 halogenated alkyl; and R3 is one or more of hydrogen, halogen,hydroxyl, nitryl, C1-4 alkyl or C1-4 halogenated alkyl. The novel quinazolinone compound provided by the invention has a novel structure, has good inhibition effect on various tumor cells, has high selectivity with BLM protein, has high combining capacity, can significantly induce DNA injury, has low toxicity on normal cells and has wide application space in preparation of anti-tumor medicines.

Description

Technical field [0001] The present invention relates to the technical field of medicinal chemistry, and more specifically, to a novel quinazolinone compound and a preparation method and application thereof. Background technique [0002] Malignant tumors are a major category of diseases that endanger human health. According to the World Health Organization (WHO) statistics, 8 million people die from cancer every year in the world, and nearly 2 million people die from cancer every year in China. Although the drug treatment of tumor has made great progress, it has become an indispensable main measure of current clinical treatment. However, problems such as high toxicity, side effects and drug resistance are still the main obstacles facing clinical tumor drug treatment. The international medical community regards the development and targeted therapy of innovative anti-tumor drugs with new targets as a new hope to change the status quo of tumor treatment, and also the leading directi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D239/90A61P35/00A61P35/02A61K31/517
CPCA61P35/00A61P35/02C07D239/90
Inventor 黄志纾陈硕斌王晨曦涂嘉莉张子林
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products